This study highlights the efficacy of #Claudin18.2-targeted IL-7/XCL1 armored CAR-T cells, demonstrating enhanced tumor regression and immune remodeling in preclinical and clinical #DigestiveTractCancer models.

#STTT #OpenAccess: doi.org/10.1038/s413...